PROSTVAC(TM) data accepted for an oral presentation at the ASCO Annual Meeting

Bavarian Nordic announced today that a PROSTVAC(TM) abstract has been
accepted for presentation at the 2009 American Society of Clinical
Oncology (ASCO) Annual Meeting in Orlando May 29 to June 2, 2009.
ASCO is the world's leading cancer organization.

Data from a Phase 2 prospective randomized placebo-controlled study
of 125 patients with advanced prostate cancer will be presented by
Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and
the Dana-Farber Cancer Institute who is the principal investigator of
the study. The presentation will take place on May 30, 2009 at 5:00
PM EDT

Bavarian Nordic previously reported data from this study, showing
that patients receiving PROSTVAC(TM) had a statistically
significantly longer median overall survival by 8.5 months (p=0.015)
compared to the control group. Currently the only approved treatment
for advanced prostate cancer extends median overall survival by an
average of 2.4 months. In addition, PROSTVAC(TM) also had a very
favourable safety and tolerability profile.

PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical
development that has the potential to extend the lives of people with
advanced prostate cancer. Administered subcutaneously, it induces a
specific, targeted immune response that attacks prostate cancer
cells. Conventional chemotherapy currently used to treat prostate
cancer has limited survival rates and is often associated with
numerous side effects. In contrast, PROSTVAC(TM) has the potential to
extend survival with improved quality of life. PROSTVAC is being
developed in collaboration with the National Cancer Institute under a
Cooperative Research and Development Agreement with Bavarian Nordic's
U.S.-based subsidiary, BN ImmunoTherapeutics.

In clinical trials to date PROSTVAC(TM) and related PSA containing
poxviral vaccines have been investigated in more than 500 patients
for 10 years.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are
very pleased that ASCO has accepted the PROSTVAC(TM) study as an oral
presentation at this year's annual meeting. This is truly encouraging
and it solidifies our decision to take PROSTVAC(TM) into Phase 3 in
2010 based on the promising data, that we have already reported with
this therapeutic vaccine."



Asger Aamund
Chairman


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64